We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 'MARCH-IN' ORDERS ON PFIZER'S XALATAN REJECTED BY NIH
'MARCH-IN' ORDERS ON PFIZER'S XALATAN REJECTED BY NIH
October 5, 2004
NIH has rejected a petition by an advocacy group seeking to break patents on Pfizer’s glaucoma drug Xalatan so that licenses could be issued for generic competition.